AstraZeneca Enters $40 Million Drug Discovery Deal With Insitro
The collaboration will identify drug targets and develop therapeutics for MASH and cardiomyopathies. AstraZeneca will make an upfront payment of $40 million.
The collaboration will identify drug targets and develop therapeutics for MASH and cardiomyopathies. AstraZeneca will make an upfront payment of $40 million.